StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly erbitux (cetuximab) — Worldwide revenue YoY (%) [legacy] (%)

Quarterly figures from Eli Lilly's filings and investor materials

QuarterlyAnnual
Latest, Q3 2024
-1.0%
Period ended Sep 30, 2024
Change on a year earlier
-7.0 pts
6.0% in Q3 2023
History
20 quarters
Since Q1 2018
Sources
20
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedErbitux (cetuximab) — Worldwide revenue YoY (%) [legacy] (%)Year on yearSource
Q3 2024Sep 30, 2024-1.0%-7.0 ptsForm 10-Q FY2024Q3 (filed 2024-10-30) ↗
Q2 2024Jun 30, 2024-4.0%-19.0 ptsForm 10-Q FY2024Q2 (filed 2024-08-08) ↗
Q1 2024Mar 31, 202411.0%+5.0 ptsForm 10-Q FY2024Q1 (filed 2024-04-30) ↗
Q3 2023Sep 30, 20236.0%-2.0 ptsForm 10-Q FY2023Q3 (filed 2023-11-02) ↗
Q2 2023Jun 30, 202315.0%+19.0 ptsForm 10-Q FY2023Q2 (filed 2023-08-08) ↗
Q1 2023Mar 31, 20236.0%–Form 10-Q FY2023Q1 (filed 2023-04-27) ↗
Q3 2022Sep 30, 20228.0%+10.0 ptsForm 10-Q FY2022Q3 (filed 2022-11-01) ↗
Q2 2022Jun 30, 2022-4.0%-18.0 ptsForm 10-Q FY2022Q2 (filed 2022-08-04) ↗
Q3 2021Sep 30, 2021-2.0%-8.0 ptsForm 10-Q FY2021Q3 (filed 2021-10-27) ↗
Q2 2021Jun 30, 202114.0%+33.0 ptsForm 10-Q FY2021Q2 (filed 2021-08-03) ↗
Q1 2021Mar 31, 2021-6.0%-16.0 ptsForm 10-Q FY2021Q1 (filed 2021-04-30) ↗
Q3 2020Sep 30, 20206.0%+25.0 ptsForm 10-Q FY2020Q3 (filed 2020-10-28) ↗
Q2 2020Jun 30, 2020-19.0%-15.0 ptsForm 10-Q FY2020Q2 (filed 2020-07-31) ↗
Q1 2020Mar 31, 202010.0%+31.0 ptsForm 10-Q FY2020Q1 (filed 2020-05-01) ↗
Q3 2019Sep 30, 2019-19.0%-17.0 ptsForm 10-Q FY2019Q3 (filed 2019-10-25) ↗
Q2 2019Jun 30, 2019-4.0%-9.0 ptsForm 10-Q FY2019Q2 (filed 2019-08-02) ↗

Cite this data

StockData. (2026). Eli Lilly Erbitux (cetuximab) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q1 2018–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_erbitux_yoy

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.